Literature DB >> 35290551

Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders.

Prashant Tarale1,2, Mahabub Maraj Alam3.   

Abstract

Colony Stimulating Factor-1 (CSF-1)/Colony Stimulating Factor-1 Receptor (CSF-1R) signaling axis plays an essential role in the development, maintenance, and proliferation of macrophage lineage cells. Within the central nervous system, CSF-1R signaling primarily maintains microglial homeostasis. Microglia, being the resident macrophage and first responder to any neurological insults, plays critical importance in overall health of the human brain. Aberrant and sustained activation of microglia along with continued proliferation and release of neurotoxic proinflammatory cytokines have been reported in various neurological and neurodegenerative diseases. Therefore, halting the neuroinflammatory pathway via targeting microglial proliferation, which depends on CSF-1R signaling, has emerged as a potential therapeutic target for neurological disorders. However, apart from regulating the microglial function, recently it has been discovered that CSF-1R has much broader role in central nervous system. These findings limit the therapeutic utility of CSF-1R inhibitors but also highlight the need for a complete understanding of CSF-1R function within the central nervous system. Moreover, it has been found that selective inhibitors of CSF-1R may be more efficient in avoiding non-specific targeting and associated side effects. Short-term depletion of microglial population in diseased conditions have also been found to be beneficial; however, the dose and therapeutic window for optimum effects may need to be standardized further.This review summarizes the present understanding of CSF-1R function within the central nervous system. We discuss the CSF-1R signaling in the context of microglia function, crosstalk between microglia and astroglia, and regulation of neuronal cell function. We also discuss a few of the neurological disorders with a focus on the utility of CSF-1R inhibitors as potential therapeutic strategy for halting the progression of neurological diseases.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CSF-1; CSF-1R inhibitor; Microglia; Neurodegenerative disease; Neuroinflammation

Mesh:

Substances:

Year:  2022        PMID: 35290551     DOI: 10.1007/s10787-022-00958-4

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  164 in total

1.  Local self-renewal can sustain CNS microglia maintenance and function throughout adult life.

Authors:  Bahareh Ajami; Jami L Bennett; Charles Krieger; Wolfram Tetzlaff; Fabio M V Rossi
Journal:  Nat Neurosci       Date:  2007-11-18       Impact factor: 24.884

2.  Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.

Authors:  Leila Akkari; Robert L Bowman; Jeremy Tessier; Florian Klemm; Shanna M Handgraaf; Marnix de Groot; Daniela F Quail; Lucie Tillard; Jules Gadiot; Jason T Huse; Dieta Brandsma; Johan Westerga; Colin Watts; Johanna A Joyce
Journal:  Sci Transl Med       Date:  2020-07-15       Impact factor: 17.956

Review 3.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms.

Authors:  Michelle L Block; Luigi Zecca; Jau-Shyong Hong
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

4.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Diana Moughon; Joey R Orpilla; Namjo P Shin; Shaina Sedighim; Janet Treger; Sylvia Odesa; Alexander Tucker; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

5.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Authors:  Nicholas Butowski; Howard Colman; John F De Groot; Antonio M Omuro; Lakshmi Nayak; Patrick Y Wen; Timothy F Cloughesy; Adhirai Marimuthu; Sam Haidar; Arie Perry; Jason Huse; Joanna Phillips; Brian L West; Keith B Nolop; Henry H Hsu; Keith L Ligon; Annette M Molinaro; Michael Prados
Journal:  Neuro Oncol       Date:  2015-10-08       Impact factor: 12.300

6.  Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis.

Authors:  Nozha Borjini; Mercedes Fernández; Luciana Giardino; Laura Calzà
Journal:  J Neuroinflammation       Date:  2016-11-15       Impact factor: 8.322

7.  Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.

Authors:  Nicolau Beckmann; Elisa Giorgetti; Anna Neuhaus; Stefan Zurbruegg; Nathalie Accart; Paul Smith; Julien Perdoux; Ludovic Perrot; Mark Nash; Sandrine Desrayaud; Peter Wipfli; Wilfried Frieauff; Derya R Shimshek
Journal:  Acta Neuropathol Commun       Date:  2018-02-15       Impact factor: 7.801

8.  Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.

Authors:  Brooke Benner; Logan Good; Dionisia Quiroga; Thomas E Schultz; Mahmoud Kassem; William E Carson; Mathew A Cherian; Sagar Sardesai; Robert Wesolowski
Journal:  Drug Des Devel Ther       Date:  2020-05-04       Impact factor: 4.162

Review 9.  The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.

Authors:  L Bingle; N J Brown; Claire E Lewis
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

Review 10.  Glial-mediated inflammation underlying parkinsonism.

Authors:  Carlos Barcia
Journal:  Scientifica (Cairo)       Date:  2013-07-11
View more
  2 in total

1.  Two Novel Intronic Mutations in the CSF1R Gene in Two Families With CSF1R-Microglial Encephalopathy.

Authors:  Jiwei Jiang; Wenyi Li; Xiaohong Wang; Zhongli Du; Jinlong Chen; Yaou Liu; Wei Li; Zhonghua Lu; Yanli Wang; Jun Xu
Journal:  Front Cell Dev Biol       Date:  2022-05-24

2.  Microbial neuraminidase induces TLR4-dependent long-term immune priming in the brain.

Authors:  María Del Mar Fernández-Arjona; Ana León-Rodríguez; Jesús M Grondona; María Dolores López-Ávalos
Journal:  Front Cell Neurosci       Date:  2022-07-28       Impact factor: 6.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.